Could a common muscle relaxant cut narcotic use after hysterectomy?
NCT ID NCT07664956
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding cyclobenzaprine, a muscle relaxant, to standard pain medicines (ibuprofen, acetaminophen, and short-term narcotics) improves pain control and reduces narcotic use after minimally invasive hysterectomy. About 36 women undergoing laparoscopic hysterectomy will be randomly assigned to receive either cyclobenzaprine or a placebo for one week after surgery. Pain scores and medication use will be tracked.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Cyclobenzaprine (a muscle relaxant)
- What this could lead to
- If it works, this could offer a better pain management option after hysterectomy, reducing the need for narcotics.
- What could go wrong
- This is a small, early-phase trial with only 36 participants, so results may not apply widely. The benefit may be small or not statistically significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 36 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age \>18yo * Female * English speaking * Undergoing (robotic assisted or classic) total laparoscopic hysterectomy ± unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy * If other procedures such as lysis of adhesions, excision of endometriosis, or ureterolysis are indicated based on intraoperative evaluation, those patients may still be included * Surgery took place at ChristianaCare Hospitals * No allergies or contraindications to standard of care post operative pain medications (acetaminophen, NSAIDs, narcotics) or cyclobenzaprine Exclusion Criteria: * Age \<18yo * Male * Pregnant, breastfeeding * Non-English speaking * Primary procedures other than laparoscopic hysterectomy * Laparoscopic myomectomy * Laparoscopic resection of endometriosis * Laparoscopic unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy ± unilateral or bilateral cystectomy without hysterectomy * Hysteroscopic procedures * Bartholin gland marsupialization * Operations that are scheduled as or converted to the open approach * Procedures with planned or unplanned bladder or bowel surgery * Allergies or contraindications to standard post operative pain control medications (acetaminophen, NSAIDs, narcotics), such as kidney or liver damage/failure, bariatric surgery, history of gastric ulcer, etc. * Chronic pain issues, whether self-diagnosed or by a physician, currently undergoing management * Currently undergoing medication assisted treatment for opioid use disorder * Currently using opioids consistently * Allergies or contraindications to cyclobenzaprine: * Absolute: use of MAO inhibitors within 14 days, recent heart attack, congestive heart failure, heart block or other conduction abnormalities, cardiac arrhythmias, hyperthyroidism, history of serotonin syndrome * Allergies or contraindications to inactive ingredients in Flexeril, such as lactose * Patient's receiving gabapentin at baseline or postoperatively, due to potential sedating effects, or other sedating drugs such as scheduled benzodiazepines and barbiturates
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Abnormal uterine bleeding, unspecified are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
ChristianaCare Health System
Newark, Delaware, 19718, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Pre-Surgery pelvic floor therapy stop endometriosis pain after the operation?
- Appendix: the hidden driver of endometriosis pain?
- Allergy pill put to the test against endometriosis pain
- Can culturally adapted physiotherapy ease chronic pelvic pain?
- Can a Nerve-Pain drug quiet chronic pelvic pain?
- Can ultrasound and tissue clues reveal which endometriosis lesions carry cancer risk?